Senolytics: Dasatinib + Quercetin

Dasatinib plus quercetin, discovered at the Mayo Clinic, is the first senolytic protocol to selectively eliminate senescent cells. In the first human trial (PMID 31542391) for idiopathic pulmonary fibrosis, D+Q reduced p16INK4a-positive cells by 35% and lowered inflammatory cytokines IL-1α and IL-6. Senescent cells drive aging via the SASP cocktail, accumulating in tissues and causing chronic inflammation. Intermittent pulse dosing—2–3 consecutive days per month—targets complementary anti-apoptotic pathways exploited only in senescent cells. Preclinical evidence spans 40+ age-related conditions. This protocol requires physician oversight due to dasatinib's prescription status and interaction risks.